The Capital Fund Management S.A. Buys Shares of 42,521 Radius Health Inc. (RDUS)

The Capital Fund Management S.A. Buys Shares of 42,521 Radius Health Inc. (RDUS)

Capital Fund Management S.A. purchased a new stake in shares of Radius Health Inc. (NASDAQ:RDUS) during the third quarter, Holdings Channel reports. The firm purchased 42,521 shares of the biopharmaceutical company’s stock, valued at approximately $2,300,000.

A number of other hedge funds have also bought and sold shares of RDUS. Vanguard Group Inc. raised its stake in Radius Health by 13.5% in the second quarter. Vanguard Group Inc. now owns 2,615,168 shares of the biopharmaceutical company’s stock worth $96,107,000 after buying an additional 311,547 shares in the last quarter. Farallon Capital Management LLC increased its position in Radius Health by 22.4% in the second quarter. Farallon Capital Management LLC now owns 1,535,000 shares of the biopharmaceutical company’s stock worth $56,411,000 after buying an additional 281,305 shares during the last quarter. Royal Bank of Canada increased its position in Radius Health by 4.3% in the second quarter. Royal Bank of Canada now owns 836,118 shares of the biopharmaceutical company’s stock worth $30,729,000 after buying an additional 34,694 shares during the last quarter. Fiera Capital Corp bought a new position in Radius Health during the second quarter worth about $21,097,000. Finally, Pictet Asset Management Ltd. increased its position in Radius Health by 1,656.6% in the second quarter. Pictet Asset Management Ltd. now owns 216,060 shares of the biopharmaceutical company’s stock worth $7,834,000 after buying an additional 203,760 shares during the last quarter. Institutional investors and hedge funds own 96.47% of the company’s stock.

Radius Health Inc. (NASDAQ:RDUS) traded up 0.31% during midday trading on Thursday, hitting $44.82. 517,883 shares of the stock were exchanged. Radius Health Inc. has a 12 month low of $24.75 and a 12 month high of $59.88. The company’s market cap is $1.93 billion. The firm’s 50 day moving average price is $43.79 and its 200 day moving average price is $48.78.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by $0.04. During the same period in the previous year, the firm earned ($0.68) EPS. On average, equities research analysts forecast that Radius Health Inc. will post ($4.41) earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on RDUS shares. Cantor Fitzgerald reissued a “buy” rating and issued a $70.00 price target on shares of Radius Health in a research note on Thursday, November 3rd. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the company a “buy” rating in a research note on Wednesday, September 28th. Cowen and Company reaffirmed a “buy” rating on shares of Radius Health in a research note on Wednesday, September 28th. HC Wainwright raised their target price on shares of Radius Health from $55.00 to $71.00 and gave the company a “buy” rating in a research note on Wednesday, September 21st. Finally, Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $61.50.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc. (NASDAQ:RDUS).

Related posts

Leave a Comment